stonks4u
Sign up free
KURA logo

KURA Kura Oncology, Inc.

NASDAQ · Biotechnology · Healthcare

$10.86
+0.77 (+7.63%)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapie…

Market Cap: $964.09Mkuraoncology.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

149
5083116149
Aug 10Aug 12

Quote

Day Range
$9.91 – $11.03
52-Week Range
$6.95 – $12.49
Volume
$1.85M
Market Cap
$964.09M
50-Day Avg
$10.15
200-Day Avg
$9.64
Prev Close
$10.09
Open
$9.98

Valuation & Ratios

P/E Ratio
-3.27
EPS
$-3.18
P/B Ratio
5.23
P/S Ratio
13.50
Debt/Equity
0.12
Current Ratio
6.06
Dividend Yield
+0.0%
Gross Margin
+99.9%

Returns & Efficiency

Return on Equity
-160.0%
Return on Assets
-37.7%
FCF Yield
-7.8%
EV/EBITDA
-2.84

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$67.48M$-278.67M$-3.18
2024$53.88M$-173.98M$-2.02
2023$0.00$-152.63M$-2.08
2022$0.00$-135.84M$-2.03
2021$0.00$-130.47M$-1.97

Social Signal Score

51
5d
51
4 mentions
—
30d
51
5 mentions
—
60d
51
5 mentions
—
90d
51
5 mentions
—
news: 5

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-0.83 per share

3of 7 quarters beat consensus

Typical surprise -27.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.77 vs $-0.88beat
  • Tue, May 12$-0.83 vs $-0.88beat
  • Thu, Mar 5$-0.92 vs $-0.72miss
  • Tue, Nov 4$-0.85 vs $-0.57miss
  • Thu, Aug 7$-0.75 vs $0.15miss
  • Thu, May 1$-0.66 vs $-0.51miss

Estimates and results for KURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

KURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (5)

  • Newsseekingalpha.com·2d ago·Positive

    Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·2d ago·Negative

    Kura Oncology Q2 Earnings Call Highlights Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.

    View source ↗
  • Newszacks.com·2d ago·Neutral

    Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.75 per share a year ago.

    View source ↗
  • Newsglobenewswire.com·2d ago·Neutral

    Kura Oncology Reports Second Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –

    View source ↗
  • Newsglobenewswire.com·5d ago·Neutral

    Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity – Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –

    View source ↗